Cardioprotective Properties of Omecamtiv Mecarbil against Ischemia and Reperfusion Injury

Omecamtiv mecarbil (OM) is a first-in-class myosin activator. It was developed as a new inotropic therapy option for heart failure and is currently the object of a phase 3 clinical trial program. OM activates ryanodine receptors, which were shown to be involved in cardioprotection induced by conditi...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Clin Med
Päätekijät: Stroethoff, Martin, Behmenburg, Friederike, Meierkord, Simon, Bunte, Sebastian, Mayer, Felix, Mathes, Alexander, Heinen, André, Hollmann, Markus W., Huhn, Ragnar
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: MDPI 2019
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6463149/
https://ncbi.nlm.nih.gov/pubmed/30889854
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm8030375
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia